Christopher Prior is the new chief executive officer at Phase Bioscience (www.phasebio.com), replacing M. Nixon Ellis who left to become CEO at Argolyn Bioscience. Prior was chief scientific officer at BioRexis and also founded Principia Pharmaceuticals and was an executive at Human Genome Sciences, which acquired Principia. Investors in PhaseBio include Hatteras, Fletcher Spaght Venture Partners and Johnson and Johnson Development.
CED News
« Pozen’s Treximet wins FDA Approval | Main | UNC Charlotte’s Five Ventures Winners Named »